We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.45B
AUM Growth
-$251M
Cap. Flow
+$217M
Cap. Flow %
8.85%
Top 10 Hldgs %
50.47%
Holding
123
New
19
Increased
24
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.2M
2
GOSS icon
Gossamer Bio
GOSS
+$34.6M
3
XLRN
Acceleron Pharma
XLRN
+$26.3M
4
EPZM
Epizyme, Inc
EPZM
+$19.6M
5
BPMC
Blueprint Medicines
BPMC
+$18.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$10.4M
2
BLUE
bluebird bio
BLUE
+$10.2M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10M
4
ANAB icon
AnaptysBio
ANAB
+$9.57M
5
ARGX icon
argenx
ARGX
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 65.35%
2 Consumer Discretionary 16.48%
3 Miscellaneous 14.54%
4 Technology 3.08%
5 Real Estate 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
1
Lexicon Pharmaceuticals
LXRX
$850M
$335M 13.68%
60,240,864
– –
WW
2
DELISTED
WW International
WW
$299M 12.19%
14,818,300
– –
MRNA icon
3
Moderna
MRNA
$57.1B
$102M 4.16%
5,006,298
-250,000
-5% -$4.64M
ONC
4
BeOne Medicines Ltd
ONC
$39.2B
$79.2M 3.23%
600,000
– –
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$76.8M 3.14%
1,650,000
+600,000
+57% +$26.3M
NVDA icon
6
NVIDIA
NVDA
$5.12T
$75.4M 3.08%
+16,800,000
New +$65.2M
BABA icon
7
Alibaba
BABA
$272B
$75.2M 3.07%
412,000
– –
CELG
8
CALL
DELISTED
Celgene Corp
CELG
$70.8M 2.89%
750,000
-250,000
-25% -$21.9M
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$68M 2.78%
850,000
+250,000
+42% +$18.5M
BAC icon
10
CALL
Bank of America
BAC
$415B
$55.2M 2.25%
2,000,000
-2,500,000
-56% -$70.7M
RUBY
11
DELISTED
Rubius Therapeutics, Inc
RUBY
$52.6M 2.15%
2,908,791
– –
ARRY
12
DELISTED
Array Biopharma Inc
ARRY
$48.8M 1.99%
2,000,000
-500,000
-20% -$10.4M
GS icon
13
CALL
Goldman Sachs
GS
$280B
$48M 1.96%
250,000
– –
ATRA icon
14
Atara Biotherapeutics
ATRA
$91.3M
$45.7M 1.87%
46,000
+6,000
+15% +$5.57M
SRRK icon
15
Scholar Rock
SRRK
$5.75B
$44.1M 1.8%
2,346,040
+50,000
+2% +$880K
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$32.3B
$42.1M 1.72%
450,000
-50,000
-10% -$4.18M
GM icon
17
CALL
General Motors
GM
$74.9B
$37.1M 1.51%
1,000,000
-2,500,000
-71% -$95M
GOSS icon
18
Gossamer Bio
GOSS
$63.6M
$36M 1.47%
+20,737
New +$34.6M
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
$35.4M 1.44%
2,600,000
-400,000
-13% -$4.89M
FATE icon
20
Fate Therapeutics
FATE
$274M
$31.6M 1.29%
1,800,000
-350,000
-16% -$5.52M
IFRX icon
21
InflaRx
IFRX
$307M
$31.2M 1.27%
825,000
+325,000
+65% +$12.1M
BMY icon
22
CALL
Bristol-Myers Squibb
BMY
$130B
$31M 1.27%
650,000
+100,000
+18% +$4.98M
NKTR icon
23
Nektar Therapeutics
NKTR
$2.26B
$30.2M 1.23%
60,000
+6,667
+13% +$3.95M
AGIO icon
24
Agios Pharmaceuticals
AGIO
$1.94B
$27M 1.1%
400,000
– –
ARGX icon
25
argenx
ARGX
$61.6B
$25M 1.02%
200,000
-70,000
-26% -$8.23M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2019 Portfolio in Review

As of Q1 2019, Artal Group held 123 positions worth $2.45B, down 9.3% from $2.7B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $217M of net new capital in Q1 2019, opening 19 new positions and adding to 24 existing holdings. Its largest new stake was NVIDIA: 16,800,000 shares worth $75.4M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.4M trimmed.

  • Artal Group's largest Q1 2019 buy was NVIDIA: 16,800,000 shares worth $75.4M.
  • Artal Group added most to Acceleron Pharma in Q1 2019, an estimated $26.3M increase.
  • Artal Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $10.4M.
  • Artal Group fully exited Clementia Pharmaceuticals Inc. in Q1 2019, selling an estimated $10M.
  • Artal Group's ten largest holdings make up 50% of its $2.45B portfolio in Q1 2019.
  • Artal Group opened 19 new positions and closed 19 in Q1 2019.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $2.45B.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.